Quince Therapeutics (NASDAQ:QNCX) Receives “Buy” Rating from D. Boral Capital

Quince Therapeutics (NASDAQ:QNCX)‘s stock had its “buy” rating reissued by equities research analysts at D. Boral Capital in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $12.00 price target on the stock.

QNCX has been the subject of several other research reports. RODMAN&RENSHAW raised shares of Quince Therapeutics to a “strong-buy” rating in a research report on Tuesday, October 29th. Maxim Group initiated coverage on shares of Quince Therapeutics in a research report on Thursday, November 7th. They issued a “buy” rating and a $6.00 price objective for the company. EF Hutton Acquisition Co. I upgraded Quince Therapeutics to a “strong-buy” rating in a research note on Tuesday, October 22nd. Brookline Capital Management initiated coverage on shares of Quince Therapeutics in a research note on Wednesday, December 18th. They issued a “buy” rating and a $9.00 target price on the stock. Finally, Rodman & Renshaw started coverage on Quince Therapeutics in a report on Tuesday, October 29th. They issued a “buy” rating and a $11.00 price objective for the company. Four equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $9.50.

Quince Therapeutics Price Performance

Shares of NASDAQ QNCX opened at $1.55 on Wednesday. The company has a debt-to-equity ratio of 0.33, a current ratio of 9.53 and a quick ratio of 9.53. Quince Therapeutics has a 1-year low of $0.51 and a 1-year high of $2.45. The company has a market capitalization of $68.20 million, a price-to-earnings ratio of -1.25 and a beta of 0.61. The business has a 50-day moving average of $1.82 and a 200-day moving average of $1.26.

Institutional Investors Weigh In On Quince Therapeutics

An institutional investor recently raised its position in Quince Therapeutics stock. Geode Capital Management LLC boosted its position in shares of Quince Therapeutics, Inc. (NASDAQ:QNCX) by 24.2% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 339,125 shares of the company’s stock after buying an additional 66,170 shares during the quarter. Geode Capital Management LLC owned 0.78% of Quince Therapeutics worth $263,000 at the end of the most recent quarter. Institutional investors own 30.75% of the company’s stock.

About Quince Therapeutics

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.